# Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)

> **NCT00686829** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 79 (actual)

## Conditions studied

- HIV
- HIV Infections

## Interventions

- **DRUG:** Vicriviroc maleate

## Key facts

- **NCT ID:** NCT00686829
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-30
- **Primary completion:** 2010-10-21
- **Final completion:** 2010-10-21
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2020-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00686829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00686829, "Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00686829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*